Logo
x

Search

Subscribe Now

Heart failure

Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receive the US FDA's Breakthrough Therapy Designation for the Treatment of Heart Failure with Preserved Ejection Fraction

Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receive the US FDA's Breakthrough Therapy Designation for the Treat...

  • September 10, 2021
Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment of HFpEF at ESC 2021

Boehringer Ingelheim and Eli Lilly Present Results of Jardiance (empagliflozin) in P-III EMPEROR-Preserved Trial for the Treatment...

  • August 31, 2021
AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for Heart Failure

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for Heart Failure

  • November 6, 2020
AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) to Cheplapharm

AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil +...

  • October 30, 2020
Amgen Report Mixed Results of Omecamtiv Mecarbil in P-lll GALACTIC-HF Study for Heart Failure

Amgen Report Mixed Results of Omecamtiv Mecarbil in P-lll GALACTIC-HF Study for Heart Failure

  • October 9, 2020
Medtronic Evaluates Insertable Cardiac Monitor to Identify Patients at High Risk of Worsening Heart Failure

Medtronic Evaluates Insertable Cardiac Monitor to Identify Patients at High Risk of Worsening Heart Failure

  • September 25, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.